More information on our approach for specific targeting and killing of cancer cells.
In recognition of the significant strides made in Phase Ia and Phase Ib, the Georgia Research Alliance has awarded a $25,000 Phase Ic grant to Annate Bitherapeutics and the Hajduk Lab at the University of Georgia. This grant will specifically support the advancement of proof-of-concept animal studies, a critical step in the development of their innovative therapeutic against Multiple Myeloma. Read More ›
